DOCSLIB.ORG

Thalidomide in Ankylosing Spondylitis F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thalidomide in Ankylosing Spondylitis F Thalidomide in ankylosing spondylitis F. Huang1, J.C.C. Wei2, M. Breban3 1Chinese PLA General Hospital, Beijing, ABSTRACT born to mothers exposed to thalidomide China; 2Family Medicine Department, Despite potential side effects dominat - during their first trimester of pregnancy Chia Yi Veterans Hospital, Taiwan; ed by terat ogenicity and peri p h e ra l which lead to withdrawal of the drug 3 INSERM U567 and Service de Rhumatolo- n e u ro p at hy, thalidomide has re c e n t ly f rom the market. Unfo rt u n at e ly, t h i s gie B, Hôpital Cochin, Paris, France. been used to tre at seve re anky l o s i n g did not occur before 10,000 to 12,000 Feng Huang, MD, James C.C. Wei, MD, spondylitis (AS). Over 50 patients have ch i l d ren with birth defects had been Maxime Breban, MD, PhD. been treated across several 6-12 month born from mothers exposed to the drug Please address correspondance to: open studies. A l t ogether 68% of the (6). Maxime Breban, MD, PhD, INSERM U567 and Service de Rhumatologie B, Hôpital p atients improved and the dro p - o u t Since that time however, thalidomide Cochin, 27 rue du Faubourg Saint-Jacques, rate was 19%. Inhibition of NF- B has continuously been used under re- 75014, Paris, France. and/or TNF is a putative mechanism stricted conditions, because of its re- E-mail: [email protected] for thalidomide efficacy in AS. ported efficacy on rare refractory mani- paris.fr fe s t ations involving immu n o l ogi c a l Clin Exp Rheumatol 2002; 20 (Suppl. 28): History mechanism, such as erythema nodosum S158-S161. Thalidomide ( -N-phthalimidoglutari- leprosum (ENL), chronic cutaneous lu- © Copyright CLINICAL AND EXPERIMEN- mide) is a synthetic derivative of glu- pus, Behçet’s disease, or chronic graft- TAL RHEUMATOLOGY 2002. tamic acid, which was originally devel- versus-host disease (6). More recently, oped by a German company and put on Food and Drug Administration has ap- Key words: Ankylosing spondylitis, the market as a sedative, in Canada, proved thalidomide for the treatment of spondylarthropathy, thalidomide, South America, throughout Europe and ENL in US after strict rules and regula- TNF . some countries in Asia. The drug was tions we re established between the known for rapid onset of action, lack of agency and Celgene, the US manufac- hangover, and absence of respiratory or turer. s keletal mu s cle coord i n ation impair- ment. The body’s handling of this lipo- Possible mechanism of action philic molecule is still incompletely The mechanism of action of thalido- k n own. Pharmacokinetic studies in mide is progressively broken down (6). healthy human male volunteers suggest Va rious anti-infl a m m at o ry, i m mu n o- a one compartment, first order absorp- modulatory and anti-angiogenic activi- tion and elimination model, with peak ties have been described (Table I). plasma levels reached within 4-5 hr and Most remarkably, thalidomide is a rela- a half-life of 8.7 ± 4.1 hr.Thalidomide tively weak inhibitor of TNF synthe- is metab o l i zed mainly through non- sis in vitro. At therapeutic concentra- enzymatic hydrolytic cleavage generat- tions, it reduces TNF production by ing a multitude of active intermediates approximately 40%. This TNF inhibi- with largely unknown functions (Chen tory capacity occurs at the transcrip- et al., 1989). tional level through a reduction of the In 1960, two types of major side-effects TNF mRNA half-life and is selective, we re rep o rt e d, i . e. peri p h e ral neuro- with no significant effect on cytokines pathies in patients with long-term ex- s u ch as interleukin (IL)-l, I L - 6 , a n d posure, and congenital abnormalities of granu l o cy t e - m a c ro p h a ge colony- s t i m u- the limbs (phocomelia) in ch i l d re n lating fac t o r , by human monocytes sti- Table I. Immunomodulatory and anti-inflammatory properties of thalidomide Inhibits leukocyte chemotaxis into site of inflammation Alters density of TNFa -induced adhesion molecules on leukocytes Reduces phagocytosis by polymorphonuclear leukocytes Enhances mononuclear cell production of interleukins-4 and -5; inhibits interferon-g production Inhibits production of interleukin-12 Inhibits production of TNF by monocytes and macrophages by reducing half-life of mRNA. S-158 Thalidomide in ankylosing spondylitis / F. Huang et al. mul ated with lipopoly s a c ch a ri d e wish to conceive, do not practice relia- Thalidomide use in ankylosing (LPS). ble contra c ep t i o n , or are judged by spondylitis Thalidomide’s inhibition of TNF pro- their health care provider to be inca- Up to recently, there was no effective duction is not always achieved in vivo. pable of practicing reliable contracep- therapy for patients with severe AS, re- Decreased TNFa serum concentration tion must be excluded from using tha- f ra c t o ry to non-steroidal anti-infl a m- have been described in patients suffer- lidomide. Furthermore, patient educa- matory drugs (NSAID), especially for ing from ENL or tuberculosis, treated tion about the proper and safe use of those with pre d o m i n a n t ly axial in- with thalidomide (8). However, TNFa thalidomide and serial pregnancy tests volvement. Given its pharmacological levels in blood conversely increased in are mandatory (6). properties, thalidomide has been con- t wo ra n d o m i zed controlled trials de- sidered as a putative anti-TNF agent. m o n s t rating thalidomide’s effi c a cy in Peripheral neuropathy The presence of TNF was demonstra- healing oral aphtae in the setting of Th a l i d o m i d e - a s s o c i ated peri p h e ra l ted in inflamed sacro-iliac joints of pa- HIV infection as well as reducing HIV- neuropathy has been described in detail tients affected with AS, both at messen- associated wasting. A similar observa- among the results of several large retro- ger RNA and protein levels (3). This tion was made in a study of patients spective studies published throughout observation prompted one of us to exa- with toxic ep i d e rmal necro ly s i s , i n the medical literature (6). Frequently, mine the efficacy of thalidomide in se- which outcome was adversely affected patients complain of painful paresthe- vere refractory AS. A regimen of 100- by thalidomide (18). Thus, it seems that sias and tingling sensations in the lower 300 mg/day was used.The first two thalidomide’s ability to inhibit TNFa ex t remities. Motor disturbances are patients who received the drug had a may depend on the stimulus or cellular generally mild and reversible on dis- clear benefit from thalidomide (5). Ef- source of cytokine production (6). continuation of the drug, whereas sen- ficacy of the drug concerned both axial Besides pro - i n fl a m m at o ry cy t o k i n e s sory symptoms may persist or incom- and peripheral clinical manifestations, inhibition, thalidomide exerts other in pletely resolve. The issue of irreversi- and also biological markers of inflam- vi t r o im mu n o m o d u l a ting activi t i e s , su c h bility is clouded by the retrospective mation (ESR and CRP). One of the 2 as T-cell costimu l at i o n , t h e reby en- nature of these studies and the collec- patients had prompt relapse after dis- hancing T cell response.This costimu- tion of data from patients whose condi- continuation of the drug, whereas the l at o ry effect ap p e a rs gre ater on the tions may themselves produce neuro- second was lost of follow-up. Efficacy CD8+ T cells than on the CD4+ T cells pathy. The reported incidence of tha- of thalidomide resumed after reintro- (16). There is no evidence that thalido- lidomide neuropathy varies from 0.5% ducing the treatment in the first patient. mide possesses immu n o s u p p re s s ive to 50% between series. Gardner-Med- Since this initial description, 10 addi- properties, and the drug has not been win and Powell have published guide- tional SpA patients have been treated a s s o c i ated with opportunistic infe c- lines for the use of electrophysiologic by the same author (4, 10). The dura- tions. A n t i a n gi ogenic pro p e rties of studies to monitor for neuro t ox i c i t y. tion of tre atment was 6 months fo l- thalidomide have also been found (9). They suggest baseline electromyogram lowed by a carry-over observation peri- Most recently, blocking of NF-kB acti- and nerve conduction velocity study re- od of 4 months. Of 12 patients enrolled vation through a mechanism that in- p e ated at 10 g or 6-month interva l s in this small-size open-labeled study, 5 volves the inhibition of IkB kinase was (which ever comes first) during treat- stopped thalidomide before 6 months shown with thalidomide, and was pro- ment. A decline in the sensory nerve because of side-effects. Evidence of posed as an upstream event responsible action potential of 50% or more, sub- clinical effic a c y was found in 7 of 12 pa- for the diffe rent actions of the dru g je c t i ve neurol o gic complaints at month- tients, among whom 2 achieved a re- (14).
Load more

Recommended publications
  • Clinical Policy: Baricitinib (Olumiant) Reference Number: ERX.SPA.291 Effective Date: 07.24.18 Last Review Date: 11.18 Revision Log
    Clinical Policy: Baricitinib (Olumiant) Reference Number: ERX.SPA.291 Effective Date: 07.24.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Baricitinib (Olumiant®) is Janus kinase (JAK) inhibitor. FDA Approved Indication(s) Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Limitation(s) of use: Use of Olumiant in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Olumiant is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Rheumatoid Arthritis (must meet all): 1. Diagnosis of RA; 2. Prescribed by or in consultation with a rheumatologist; 3. Age ≥ 18 years; 4. Member meets one of the following (a or b): a. Failure of a ≥ 3 consecutive month trial of methotrexate (MTX) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; b. If intolerance or contraindication to MTX (see Appendix D), failure of a ≥ 3 consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced; 5.
    [Show full text]
  • Immunosuppressant Drugs Therapy with COVID-19
    Immunosuppressant Drugs Therapy with COVID-19: Associated Risks, Drug-Drug Interactions & Contraindications Debjyoti Talukdar1, Diane Ignacio2, and Madan Mohan Gupta2 1Teerthanker Mahaveer University 2The University of the West Indies at St Augustine September 24, 2020 Abstract Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase the mortality and morbidity, as a weakened immune system can lead to longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and its associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organisation), U.S FDA (Food and Drug Administration) and other accredited global health organisa- tions. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications and drug-drug interactions. Our study will help government partners and international health organisations to better understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised and organ transplant patients will help lower the mortality and morbidity associated with the disease amid COVID-19 pandemic. 1. INTRODUCTION As per the U.S Department of Health and Human Services and U.S FDA, immunosuppressant drugs can cause susceptibility to viruses leading to infection with increase in morbidity of the disease. It can cause severe risk of illness from COVID-19 due to a weakened immune system.
    [Show full text]
  • Benlysta® (Belimumab)
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1227-6 Program Prior Authorization/Notification Medication Benlysta® (belimumab)* *This program applies to the subcutaneous formulation of belimumab P&T Approval Date 9/2017, 9/2018, 9/2019, 9/2020, 2/2021, 7/2021 Effective Date 10/1/2021; Oxford only: 10/1/2021 1. Background: Benlysta® is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy and adult patients with active lupus nephritis who are receiving standard therapy. Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics. Use of Benlysta is not recommended in these situations. 2. Coverage Criteria: A. Systemic Lupus Erythematosus 1. Initial Authorization a. Benlysta will be approved based on all of the following criteria: (1) Diagnosis of systemic lupus erythematosus -AND- (2) Laboratory testing has documented the presence of autoantibodies [e.g., ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/SSA, Anti-La/SSB] -AND- (3) Patient is currently receiving standard immunosuppressive therapy [e.g., hydroxychloroquine, chloroquine, prednisone, azathioprine, methotrexate] -AND- (4) Patient does not have severe active central nervous system lupus -AND- (5) Patient is not receiving Benlysta in combination with either of the following: (a) Biologic DMARD [e.g., Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab), Kineret (anakinra)] © 2021 UnitedHealthcare Services, Inc. 1 (b) Lupkynis (voclosporin) Authorization will be issued for 12 months.
    [Show full text]
  • Attachment: Extract from Clinical Evaluation: Etanercept
    AusPAR Attachment 2 Extract from the Clinical Evaluation Report for etanercept Proprietary Product Name: Erelzi Sponsor: Novartis Pharmaceuticals Australia Pty Ltd First round report: June 2017 Second round report: August 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. · An AusPAR is a static document; it provides information that relates to a submission at a particular point in time.
    [Show full text]
  • Heart Failure and Drug-Induced Lupus
    Unusual toxicities with TNF inhibition: Heart failure and drug-induced lupus J.J. Cush John J. Cush, MD, Chief, Rheumatology ABSTRACT demyelinating disease, cytopenias, auto- and Clinical Immunology, Presbyterian Serious and unexpected adverse events, immune disorders, and heart failure. Hospital of Dallas, Clinical Professor of such as heart failure and drug-induced Other essays in this volume address the Internal Medicine, The University of Texas lupus, have been reported in patients subject of infection (10), demyelination Southwestern Medical School, Dallas, Texas, USA. receiving TNF inhibitor therapy. These (11), and lymphoma (12). This review events generally are easily recogniz- will focus on heart failure and lupus- Please address correspondence to: John J. Cush, MD, Presbyterian Hospital able, although they cannot be predicted like disease, which are rarely seen in of Dallas, 8200 Walnut Hill Lane, Dallas, nor avoided, other than by drug avoid- association with TNF inhibitor therapy Texax 75231-4496, USA. ance altogether. Many patients have and are currently without explanation. Clin Exp Rheumatol 2004; 22 (Suppl. 35): great benefit from anti-TNF therapies. S141-S147. Their intelligent use requires a firm Sources of data © Copyright CLINICAL AND EXPERIMENTAL understanding of these rare toxicities, As a consequence of drug approval, RHEUMATOLOGY 2004. so as to minimize the morbidity associ- manufacturers have a responsibility to ated with their uncommon occurrence. collect safety data actively and report Key words: TNF inhibitors, conges- these data to the appropriate agencies. tive heart failure, drug-induced lupus, Introduction For example, in the USA a manufactur- rheumatoid arthritis. The introduction of biologic agents to er must submit periodic safety reports specifically inhibit the pro-inflammato- to the FDA twice yearly (March and ry cytokine, tumor necrosis factor (TNF), September).
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • BCMA-Targeted Immunotherapy for Multiple Myeloma Bo Yu1, Tianbo Jiang2 and Delong Liu2*
    Yu et al. Journal of Hematology & Oncology (2020) 13:125 https://doi.org/10.1186/s13045-020-00962-7 REVIEW Open Access BCMA-targeted immunotherapy for multiple myeloma Bo Yu1, Tianbo Jiang2 and Delong Liu2* Abstract B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development. Keywords: B cell maturation antigen, BCMA, Belantamab mafodotin, CAR-T, Antibody-drug conjugate, Bispecific T cell engager Introduction B cell maturation antigen (BCMA) Recent advances in novel therapeutics such as prote- BCMA is encoded by a 2.92-kb TNFRSF17 gene located asome inhibitors (PI) and immunomodulatory drugs on the short arm of chromosome 16 (16p13.13) and (IMiD) have significantly improved the treatment out- composed of 3 exons separated by 2 introns (Fig. 1). comes in patients with multiple myeloma (MM) [1–8]. BCMA is a 184 amino acid and 20.2-kDa type III trans- However, most MM patients eventually relapse due to membrane glycoprotein, with the extracellular N the development of drug resistance [9]. In addition, terminus containing a conserved motif of 6 cysteines many of the current popular target antigens, such as [18–21].
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08.16 Last Review Date: 02.21 Coding Implications Line of Business: Medicaid Revision Log
    Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08.16 Last Review Date: 02.21 Coding Implications Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Etanercept (Enbrel®) is a tumor necrosis factor (TNF) blocker. FDA Approved Indication(s) Enbrel is indicated for the treatment of: • For reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. • For reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older • For reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used with or without methotrexate. • For reducing signs and symptoms in patients with active ankylosing spondylitis (AS) • For the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Enbrel is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Ankylosing Spondylitis (must meet all): 1. Diagnosis of AS; 2. Prescribed by or in consultation with a rheumatologist; 3.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-A Inhibitor Therapy Jeannina A
    Drugs 2009; 69 (11): 1403-1415 THERAPY IN PRACTICE 0012-6667/09/0011-1403/$55.55/0 ª 2009 Adis Data Information BV. All rights reserved. Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-a Inhibitor Therapy Jeannina A. Smith and Carol A. Kauffman Division of Infectious Diseases, University of Michigan Medical School, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, USA Contents Abstract. 1403 1. Role of Tumour Necrosis Factor (TNF)-a in Immunity and Chronic Inflammatory Diseases . 1404 2. Currently Licensed TNFa Inhibitors . 1404 3. TNFa Inhibitors and Infection with Intracellular Pathogens . 1405 4. TNFa Inhibitors and Infection with Endemic Mycoses . 1406 4.1 Histoplasmosis . 1406 4.2 Blastomycosis . 1408 4.3 Coccidioidomycosis. 1410 5. Prevention of Endemic Mycoses among Patients Receiving TNFa Inhibitor Therapy . 1412 6. Conclusions . 1413 Abstract Tumour necrosis factor (TNF)-a inhibitors are widely used agents in the treatment of a variety of inflammatory and granulomatous diseases. It has long been appreciated that these agents confer an increased risk of tubercu- losis; however, more recently it has been recognized that patients being treated with TNFa inhibitors are also at significant risk for infection with the endemic fungi, in particular Histoplasma capsulatum, and when infected, to develop severe disseminated infection. Patients often present in an atypical manner and the symptoms of the fungal infection can be mistaken for those of the underlying disease. Thus, delay in diagnosis and treatment is common, and mortality has been high. In an attempt to increase awareness of this problem, the US FDA issued a ‘black box’ warning for clinicians in Sep- tember 2008 to alert providers of the risks of endemic fungal infections in patients treated with TNFa inhibitors.
    [Show full text]
  • Australian Public Assessment Report for Filgotinib Maleate
    Australian Public Assessment Report for Filgotinib maleate Proprietary Product Name: Jyseleca Sponsor: Gilead Sciences Pty Ltd May 2021 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]